oa SA Pharmaceutical Journal - Vortioxetine : more than just another selective serotonin reuptake inhibitor : drug info - new product focus

Volume 82, Issue 4
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Major depressive disorder (MDD) is a disabling disease with a high risk of relapse and chronicity. Despite treatment, only 30% of patients with MDD achieve full remission. Vortioxetine is a new multimodal antidepressant. It is a serotonin reuptake inhibitor, but in addition, also has direct effects on several subtypes of serotonin receptors. It has been shown to be as effective as venlafaxine, and more effective than agomelatine in improving the symptoms of MDD. In addition, vortioxetine has been shown to improve cognitive function. It may also improve sexual dysfunction in patients who have experienced antidepressant-related sexual dysfunction with other antidepressants. Vortioxetine is generally well tolerated. The most common adverse events are mild to moderate nausea, and headaches that are usually transient in nature.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error